Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis

Ayse L Mindikoglu, Matthew R Weir, Ayse L Mindikoglu, Matthew R Weir

Abstract

Background: Renal dysfunction is one of the most common complications of cirrhosis with high morbidity and mortality.

Summary: In subjects with cirrhosis, renal dysfunction can present either as a direct consequence of cirrhosis (e.g. hepatorenal syndrome type I and type II) or secondary to etiologies other than cirrhosis (chronic kidney disease due to diabetic nephropathy, prerenal azotemia), or patients with cirrhosis may have renal dysfunction resulting directly from cirrhosis and an underlying chronic kidney disease.

Key messages: Given the challenges in the differential diagnosis of renal dysfunction and insufficient accuracy of serum creatinine and creatinine-based glomerular filtration rate estimating equations in cirrhosis, there is an urgent need for more accurate biomarkers of renal dysfunction in this population. This review will discuss novel concepts for the diagnosis and classification of renal dysfunction in cirrhosis to overcome at least some of the diagnostic and therapeutic challenges. Additionally, a new classification will be proposed for renal dysfunction in cirrhosis.

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT

None of the authors has conflict of interest associated with the manuscript.

© 2013 S. Karger AG, Basel.

References

    1. Cholongitas E, Senzolo M, Patch D, Shaw S, O’Beirne J, Burroughs AK. Cirrhotics admitted to intensive care unit: The impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol. 2009;21:744–750.
    1. Gines P. Pharmacological management of hepatorenal syndrome: Lessons from non-responders. J Hepatol. 2011;55:268–269.
    1. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51:576–584.
    1. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48:2064–2077.
    1. [Accessed on january 18, 2013];Data. Available at .
    1. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International ascites club. Hepatology. 1996;23:164–176.
    1. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–1318.
    1. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, Rodes J, Gines P. Meld score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology. 2005;41:1282–1289.
    1. Easl clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.
    1. Runyon BA. Management of adult patients with ascites due to cirrhosis: An update. Hepatology. 2009;49:2087–2107.
    1. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Davenport A, Jalan R, Ronco C, Genyk Y, Arroyo V. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011;60:702–709.
    1. Kew MC, Brunt PW, Varma RR, Hourigan KJ, Williams HS, Sherlock S. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet. 1971;2:504–510.
    1. Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, Rodrigo JM, Serra MA. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006;231:70–75.
    1. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (adma) Clin Nutr. 2003;22:17–22.
    1. Nijveldt RJ, Teerlink T, van Leeuwen PA. The asymmetrical dimethylarginine (adma)-multiple organ failure hypothesis. Clin Nutr. 2003;22:99–104.
    1. Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA. Asymmetrical dimethylarginine (adma) in critically ill patients: High plasma adma concentration is an independent risk factor of icu mortality. Clin Nutr. 2003;22:23–30.
    1. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–575.
    1. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20 (Suppl 12):S60–62.
    1. Vallance P. Endothelial regulation of vascular tone. Postgrad Med J. 1992;68:697–701.
    1. Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, Rodrigo JM. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol. 2004;41:55–59.
    1. Siroen MP, van der Sijp JR, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology. 2005;41:559–565.
    1. Siroen MP, Wiest R, Richir MC, Teerlink T, Rauwerda JA, Drescher FT, Zorger N, van Leeuwen PA. Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. World J Gastroenterol. 2008;14:7214–7219.
    1. Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA. The prominent role of the liver in the elimination of asymmetric dimethylarginine (adma) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr. 2008;32:613–621.
    1. Vizzutti F, Romanelli RG, Arena U, Rega L, Brogi M, Calabresi C, Masini E, Tarquini R, Zipoli M, Boddi V, Marra F, Laffi G, Pinzani M. Adma correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest. 2007;37:509–515.
    1. Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, Sen S, Williams R, Leiper J, Vallance P, Jalan R. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology. 2007;45:62–71.
    1. Koeppen bm, stanton ba. Glomerular filtration and renal blood flow. In: Koeppen bm, stanton ba., editors. Renal physiology. 4. Philadelphia: Mosby; 2007. pp. 31–46.
    1. Rivolta R, Maggi A, Cazzaniga M, Castagnone D, Panzeri A, Solenghi D, Lorenzano E, di Palo FQ, Salerno F. Reduction of renal cortical blood flow assessed by doppler in cirrhotic patients with refractory ascites. Hepatology. 1998;28:1235–1240.
    1. Wang Y, Liu LP, Bai WY, Wen SB, Dan HJ, Luan YY, Zeng MX, Hu B. Renal haemodynamics in patients with liver cirrhosis assessed by colour ultrasonography. J Int Med Res. 2011;39:249–255.
    1. Celebi H, Donder E, Celiker H. Renal blood flow detection with doppler ultrasonography in patients with hepatic cirrhosis. Arch Intern Med. 1997;157:564–566.
    1. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014;59:1532–42.
    1. Leslie SH, Johnston B, Ralli EP. Renal function as a factor in fluid retention in patients with cirrhosis of the liver. J Clin Invest. 1951;30:1200–1207.
    1. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: Effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med. 1995;122:816–822.
    1. Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR. Renal duplex doppler ultrasonography: A noninvasive predictor of renal dysfunction and hepatorenal failure in liver disease. Hepatology. 1994;20:362–369.
    1. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P Acute Dialysis Quality Initiative w. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The second international consensus conference of the acute dialysis quality initiative (adqi) group. Crit Care. 2004;8:R204–212.
    1. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (sdma) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant. 2006;21:2446–2451.
    1. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation. 1999;99:1141–1146.
    1. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr. 2006;26:203–228.
    1. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury N. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
    1. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR for the T-AKIC. Association of aki with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57:753–62.
    1. de Carvalho JR, Villela-Nogueira CA, Luiz RR, Guzzo PL, da Silva Rosa JM, Rocha E, Moraes Coelho HS, de Mello Perez R. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J Clin Gastroenterol. 2012;46:e21–26.
    1. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131–7.
    1. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: Problems and pitfalls. Am J Kidney Dis. 2003;41:269–278.
    1. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med. 1987;82:945–952.
    1. Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: Implications for estimation of creatinine clearance. Ther Drug Monit. 1983;5:161–168.
    1. Mindikoglu AL, Regev A, Seliger SL, Magder LS. Gender disparity in liver transplant waiting-list mortality: The importance of kidney function. Liver Transpl. 2010;16:1147–1157.
    1. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–2483.
    1. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transpl. 2004;10:301–309.
    1. Skluzacek PA, Szewc RG, Nolan CR, 3rd, Riley DJ, Lee S, Pergola PE. Prediction of gfr in liver transplant candidates. Am J Kidney Dis. 2003;42:1169–1176.
    1. Cholongitas E, Marelli L, Kerry A, Goodier DW, Nair D, Thomas M, Patch D, Burroughs AK. Female liver transplant recipients with the same gfr as male recipients have lower meld scores--a systematic bias. Am J Transplant. 2007;7:685–692.
    1. Mindikoglu AL, Raufman JP, Seliger SL, Howell CD, Magder LS. Simultaneous liver-kidney versus liver transplantation alone in patients with end-stage liver disease and renal dysfunction not on dialysis. Transplant Proc. 2011;43:2669–2677.
    1. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD, 3rd, Zhang YL, Greene T, Levey AS. Estimating gfr using serum cystatin c alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with ckd. Am J Kidney Dis. 2008;51:395–406.
    1. Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J. Serum cystatin c in the united states: The third national health and nutrition examination survey (nhanes iii) Am J Kidney Dis. 2008;51:385–394.
    1. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin c for evaluation of hepatorenal syndrome. Clin Chim Acta. 2001;311:81–89.
    1. Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin c concentration as a marker of renal function in patients with cirrhosis of the liver. Gut. 2002;50:106–110.
    1. Randers E, Ivarsen P, Erlandsen EJ, Hansen EF, Aagaard NK, Bendtsen F, Vilstrup H. Plasma cystatin c as a marker of renal function in patients with liver cirrhosis. Scand J Clin Lab Invest. 2002;62:129–134.
    1. Ustundag Y, Samsar U, Acikgoz S, Cabuk M, Kiran S, Kulah E, Aydemir S. Analysis of glomerular filtration rate, serum cystatin c levels, and renal resistive index values in cirrhosis patients. Clin Chem Lab Med. 2007;45:890–894.
    1. Woitas RP, Stoffel-Wagner B, Flommersfeld S, Poege U, Schiedermaier P, Klehr HU, Spengler U, Bidlingmaier F, Sauerbruch T. Correlation of serum concentrations of cystatin c and creatinine to inulin clearance in liver cirrhosis. Clinical chemistry. 2000;46:712–715.
    1. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH. Recommendations for improving serum creatinine measurement: A report from the laboratory working group of the national kidney disease education program. Clinical chemistry. 2006;52:5–18.
    1. Daugherty NA, Hammond KB, Osberg IM. Bilirubin interference with the kinetic jaffe method for serum creatinine. Clinical chemistry. 1978;24:392–393.
    1. Poge U, Gerhardt T, Stoffel-Wagner B, Klehr HU, Sauerbruch T, Woitas RP. Calculation of glomerular filtration rate based on cystatin c in cirrhotic patients. Nephrol Dial Transplant. 2006;21:660–664.
    1. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin c, plasma creatinine and the cockcroft and gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18:2024–2031.
    1. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in ml/min from plasma cystatin c values in mg/l. Scand J Clin Lab Invest. 2004;64:25–30.
    1. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, Investigators C-E. Estimating glomerular filtration rate from serum creatinine and cystatin c. N Engl J Med. 2012;367:20–29.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
    1. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470.
    1. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner